Wegovy (semaglutide) and Zepbound (tirzepatide) are both FDA-approved for chronic weight management. Here is how they differ and how a Chicago telehealth visit can help you decide.
GLP-1 medications turn down appetite, which makes what you do eat matter more: protein, fluids, fiber, and strength training all help protect muscle and how you feel while weight comes down. Here is a practical, physician-reviewed overview for Chicago-area adults.
Chicago adults looking for a weight loss doctor can choose between an in-person office and an online obesity medicine practice, and each format has real strengths. Here is how to compare them and decide which fits your health needs, schedule, and goals.
An online weight loss doctor can evaluate your health history, discuss FDA-approved medications, and monitor your progress over secure video visits, so Chicago-area adults can get physician-supervised care without commuting to an office. Here is what a telehealth visit involves and how to choose a provider.
Many Chicago-area adults exploring medical weight loss for the first time want to know one thing before they book a consultation: will insurance pay for the medication. The answer varies by plan, diagnosis, and the specific drug prescribed, and it rarely comes down to a simple yes or no.
Zepbound remains a once-weekly injection (tirzepatide). However, Eli Lilly, the maker of Zepbound, received FDA approval on April 1, 2026 for Foundayo™ (orforglipron), a once-daily oral GLP-1 weight loss pill that can be taken any time of day, with or without food. If you were searching for “oral Zepbound,” Foundayo is almost certainly the medication you were looking for.
For years, the biggest question we heard from patients across Chicago and the western suburbs — from the Loop to Naperville to Oak Brook — was some version of: “Is there a pill version of Wegovy? I just can’t do injections.” As of January 2026, the answer is finally yes. The FDA approved the Wegovy® pill (oral semaglutide) in December 2025...
TeleSlim Clinic now offers a lower‑cost semaglutide option that makes Ozempic and Wegovy more attainable for many people in the Chicago area. For $349 per month, our subscription model aims to reduce financial hurdles while keeping physician oversight central to care.
The federal pricing initiative known as TrumpRx is changing how certain high cost anti obesity drugs are priced and distributed, opening clearer, lower cost routes for Chicago patients to access GLP 1 and GIP therapies.
In Chicago’s bustling health market, many people seek medical weight-loss solutions. Sadly, some providers promote compounded, unapproved injections of Semaglutide or Tirzepatide because they’re cheaper.
